Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
KURA Stock | USD 10.29 0.24 2.28% |
About 58% of Kura Oncology's investor base is looking to short. The analysis of the overall investor sentiment regarding Kura Oncology suggests that many traders are alarmed. The current market sentiment, together with Kura Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Kura Oncology stock news signals to limit their universe of possible portfolio assets.
Kura |
Interim analysis from Phase 1a portion of KOMET-007 shows 100 percent CR rate in NPM1-m and 83 percent CR rate in KMT2A-r 1L adverse risk AML with 73 100 percent of 1L NPM1-m and 96 percent of 1L KMT2A-r AML patients alive as of data cutoff with median follow-up of 31 and 19 weeks, respectively Promising clinical activity in RR NPM1-m and KMT2A-r AML with venaza, including ven-experienced patients Ziftomenib generally well tolerated in combination with standards of care at all dose levels studied Kura
Read at finance.yahoo.com
Kura Oncology Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kura Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kura Oncology Fundamental Analysis
We analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Kura Oncology is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Kura Oncology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kura Oncology stock to make a market-neutral strategy. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics with similar companies.
Peers
Kura Oncology Related Equities
INZY | Inozyme Pharma | 9.56 | ||||
PTGX | Protagonist Therapeutics | 2.72 | ||||
DSGN | Design Therapeutics | 1.69 | ||||
REPL | Replimune | 1.58 | ||||
KALV | Kalvista Pharmaceuticals | 1.07 | ||||
CRNX | Crinetics Pharmaceuticals | 0.97 | ||||
KNSA | Kiniksa Pharmaceuticals | 0.42 | ||||
ERAS | Erasca | 0.67 | ||||
VRDN | Viridian Therapeutics | 0.87 | ||||
COGT | Cogent Biosciences | 1.76 | ||||
MRUS | Merus BV | 1.83 | ||||
DAWN | Day One | 1.86 | ||||
LRMR | Larimar Therapeutics | 2.81 | ||||
SNDX | Syndax Pharmaceuticals | 3.98 | ||||
ZNTL | Zentalis Pharmaceuticals | 7.20 | ||||
GLUE | Monte Rosa | 7.45 |
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |